BioCentury
ARTICLE | Clinical News

Absorica regulatory update

June 4, 2012 7:00 AM UTC

FDA approved an NDA from Cipher for Absorica Cip-isotretinoin to treat severe recalcitrant nodular acne. The approval triggers a $9 million milestone payment to Cipher from Ranbaxy Laboratories Ltd. (NSE:RANBAXY; BSE:500359, Gurgaon, India), which has an exclusive license from Cipher to market the product to treat acne in the U.S. under a 2008 deal (see BioCentury, Aug. 18, 2008). Ranbaxy plans to launch Absorica in the U.S. in 4Q12. ...